PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.82%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
-14.04%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.04%
Operating expenses growth 5-10% suggests significant expansion. Howard Marks would investigate necessity.
9.04%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
104.89%
Interest expense growth above 10% signals concerning debt expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
114.37%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
48.96%
Pre-tax income growth above 15% demonstrates exceptional profitability improvement. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
135.99%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
48.96%
Net income growth above 15% demonstrates exceptional bottom-line expansion. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
53.59%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
51.99%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
10.21%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
6.42%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.